Press Release Date: Time: Contact: 24 July 2014

First Page		Document Content
Date: 2014-08-04 06:16:52 Health Emergency contraception Medicines and Healthcare products Regulatory Agency Yellow Card Scheme Levonorgestrel Birth control Ulipristal acetate Contraception Hormonal contraception Medicine Pharmacology		Press Release Date: Time: Contact: 24 July 2014 Add to Reading List Source URL: www.mhra.gov.uk Download Document from Source Website File Size: 70,92 KB Share Document on Facebook

	Articles Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis Anna F Glasier, Sharon T Cameron, Paul M Fine, Susan J S Logan, William Casale, Jennife DocID: 1gsp4 - View Document
	About HRA Pharma HRA Pharma is a leading pharmaceutical company with a unique leadership position within niche areas of women’s health and endocrinology. The company is committed to understanding evolving health needs, DocID: 1ahKh - View Document
	Monthly briefings are produced in order to help members of the media and other interested people understand the work and advice of the Scottish Medicines Consortium. The detailed advice for each medicine that DocID: 176U9 - View Document
	23 April 2015 EMA/CHMPCommittee for Medicinal Products for Human Use (CHMP) Summary of opinion 1 (post authorisation) DocID: 16soR - View Document
	Emerging Female, Male, and Post-coital methods.xls DocID: 14ij8 - View Document